A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Clinical trial NCT02203513 · TERMINATED

Trial details

NCT number: NCT02203513
Sponsor: National Cancer Institute (NCI)
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Ovarian Cancer Breast Cancer Prostate Cancer

Start date: 2015-01-20
Primary completion: 2021-08-27
Enrollment: 111

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.